Keren Skalsky

Dr. Keren Skalsky

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Keren SkalskyKeren Skalsky
Keren Skalsky
Arthur ShiyovichArthur Shiyovich
Arthur Shiyovich
TSTali Steinmetz
Tali Steinmetz
RKRan Kornowski
Ran Kornowski
Coronary artery disease is highly prevalent in patients with chronic kidney disease. The concomitant renal disease often poses a major challenge in decision making as symptoms, cardiac biomarkers and noninvasive studies for evaluation of myocardial ischemia have different sensitivity and specificity thresholds in this specific population. Moreover, the effectiveness and safety of intervention and medical treatment in those patients is of great doubt as most clinical studies exclude patients with advance CKD. In the present paper, we discuss and review the literature in the diagnosis, treatment and prevention of CAD in the acute and chronic setting, in patients with CKD.

16 February 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TATal Abu
Tal Abu
ALAmos Levi
Amos Levi
DHDavid Hasdai
David Hasdai
MKMordechai R. Kramer
Mordechai R. Kramer
TBTamir Bental
Tamir Bental
Keren SkalskyKeren Skalsky
Keren Skalsky
Background: Right heart catheterization (RHC) and echocardiography are both routinely used for pulmonary artery systolic pressure (PASP) assessment in lung transplantation (LT) candidates, although this is not mandated by current guidelines. We aimed to explore the performance of echocardiographic PASP as an indicator of pulmonary hypertension in LT candidates, in order to assess the necessity of RHC.Methods: From a retrospective registry of 393 LT candidates undergoing RHC and echocardiography during 2015–2019, patients were assessed for the presence of pulmonary hypertension (PH), defined as mean pulmonary artery pressure (mPAP) above 20 mmHg, according to two methods—echocardiography and RHC. The primary outcome was the correlation between the PASP estimated by echocardiography to that measured by RHC. Secondary outcomes were the prediction value of the echocardiographic evaluation and its accuracy.Results: The mean value of PASP estimated by echocardiography was 49.5 ± 20.0 mmHg, compared to 42.5 ± 18.0 mmHg measured by RHC. The correlation between the two measurements was moderate (Pearson’s correlation: r = 0.609,p < 0.01). Echocardiography PASP measurements were moderately discriminative to diagnose PH, with an area under the curve (AUC) of 0.72 (95% CI 0.66–0.77). Echocardiographic overestimation of PASP of more than 10 mmHg was found in 35.0% of the patients, and underestimation was found in 11.6% of the patients.Conclusion: In the pre-surgical evaluation of LT candidates, echocardiographic estimation of PASP had moderate correlation and limited accuracy compared to the PASP measured by RHC. We thus recommend performing routine RHC to all LT candidates, regardless of the echocardiographic estimation of PASP.

29 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NPNili Schamroth Pravda
Nili Schamroth Pravda
GGGregory Golovchiner
Gregory Golovchiner
GGGustavo Goldenberg
Gustavo Goldenberg
YPYgal Plakht
Ygal Plakht
MWMaya Wiessman
Maya Wiessman
AHAshraf Hamdan
Ashraf Hamdan
Introduction: Atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI) ablation has clinical significance. Identifying risk factors for AF recurrence is important. We investigated serum albumin (SA) levels (g/dL) as a prognostic factor for the recurrence of AF following cryoballoon PVI ablation. Methods: We included patients who underwent cryoballoon PVI ablation at our institution between the years 2013 and 2018. The primary outcome was recurrence of AF during follow up. Results: Our cohort consisted of 126 patients (67% males, mean age 61.8 ± 10.0 years). The pattern of AF amongst the cohort was paroxysmal in 62.5%, persistent in 25.4%, and longstanding persistent in 6.3%. Those with lower SA levels had a mean AF duration significantly less than those with higher SA levels (2.81 years, 7.34 years, and 6.37 years for SA levels of <3.8, 3.8–4.1, and ≥4.1, respectively; p = 0.003). Patients with lower SA levels were significantly more likely to have had more previous cardioversions and a larger left atrial area and volume. The mean follow-up was 380 days, in which the AF recurrence rate was 20.6%. Patients with lower SA level had significantly more AF recurrences (47.4%, 16.7%, and 2.2% for SA levels of <3.8, 3.8–4.1, and ≥4.1, respectively; p < 0.001). Upon multivariate analysis, an SA level < 3.8 was associated with a higher risk of AF recurrence (OR = 5.422 95% CI 1.134; 25.910; p < 0.001). Conclusion: SA levels were found to be a strong independent marker for AF recurrence following PVI ablation.

1 October 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
Keren SkalskyKeren Skalsky
Keren Skalsky
ALAmos Levi
Amos Levi
TBTamir Bental
Tamir Bental
HVHana Vaknin-Assa
Hana Vaknin-Assa
AAAbid Assali
Abid Assali
LPLeor Perl
Leor Perl

1 March 2021 in International Journal of Cardiology
Verified
Journal Article
Closed access
Keren SkalskyKeren Skalsky
Keren Skalsky
ASArthur Shiyovich
Arthur Shiyovich
TBTamir Bental
Tamir Bental
HVHana Vaknin-Assa
Hana Vaknin-Assa
AAAbid Assali
Abid Assali
LPLeor Perl
Leor Perl

25 October 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Arthur ShiyovichArthur Shiyovich
Arthur Shiyovich
Keren SkalskyKeren Skalsky
Keren Skalsky
TSTali Steinmetz
Tali Steinmetz
TOTal Ovdat
Tal Ovdat
AEAlon Eisen
Alon Eisen
KOKatia Orvin
Katia Orvin
Purpose: To evaluate the role of diabetes mellitus in the incidence, risk factors, and outcomes of AKI (acute kidney injury) in patients admitted with ACS (acute coronary syndrome). Methods: We performed a comparative evaluation of ACS patients with vs. without DM who developed AKI enrolled in the biennial ACS Israeli Surveys (ACSIS) between 2000 and 2018. AKI was defined as an absolute increase in serum creatinine (≥0.5 mg/dL) or above 1.5 mg/dL or new renal replacement therapy upon admission with ACS. Outcomes included 30-day major adverse cardiovascular events (MACE) and 1-year all-cause mortality. Results: The current study included a total of 16,879 patients, median age 64 (IQR 54–74), 77% males, 36% with DM. The incidence of AKI was significantly higher among patients with vs. without DM (8.4% vs. 4.7%, p < 0.001). The rates of 30-day MACE (40.8% vs. 13.4%, p < 0.001) and 1-year mortality (43.7% vs. 10%, p < 0.001) were significantly greater among diabetic patients who developed vs. those who did not develop AKI respectively, yet very similar among patients that developed AKI with vs. without DM (30-day MACE 40.8% vs. 40.3%, p = 0.9 1-year mortality 43.7 vs. 44.8%, p = 0.8, respectively). Multivariate analyses adjusted to potential confounders, showed similar independent predictors of AKI among patients with and without DM, comprising; older age, chronic kidney disease, congestive heart failure, and peripheral arterial disease. Conclusions: Although patients with DM are at much greater risk for AKI when admitted with ACS, the independent predictors of AKI and the worse patient outcomes when AKI occurs, are similar irrespective to DM status.